Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Gilead Vulnerable to ViiV As It Nears End Of HIV R&D Activity?

Executive Summary

Company hopes TAF-based combo incorporating integrase inhibitor bictegravir can help it compete with ViiV, but beyond that pipeline holds only early-stage and smaller opportunities in HIV. Analysts call on Gilead to use its cash stockpile to find its next R&D focus.

Advertisement

Related Content

Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?
Gilead's Bictegravir Data Could Mean Continued HIV Sector Dominance
Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos
Gilead Coming To The End Of HCV Road With Triple-Drug Regimen
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
When Will Gilead Make Its M&A Move?
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
Bristol's Sale Of HIV Pipeline To ViiV Signals Tightened Focus
Gilead: Three HIV Launches Expected In Near-Term Future
Gilead's HIV franchise looks secure as 'son of Viread' impresses in PhIII

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel